Evidence map›Paper›PMID 27768622›Full record

ArticleAnnals of surgery2017

Survival Benefit of Kidney Transplantation in HIV-infected Patients.

Jayme E Locke, Sally Gustafson, Shikha Mehta, Rhiannon D Reed, Brittany Shelton, Paul A MacLennan, Christine Durand, Jon Snyder, Nicholas Salkowski, Allan Massie and 2 more

Abstract readComparative Study
In one paragraph

Article in Annals of surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Safety of Kidney Transplantation from Donors with HIV.The New England journal of medicine · 2024
    Observational
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Early steps to kidney transplantation among persons with HIV and end-stage renal disease in ESRD network 6.Transplant infectious disease : an official journal of the Transplantation Society · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jayme E Locke*Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, Alabama †Scientific Registry of Transplant Recipients, Minneapolis, Minnesota ‡Johns Hopkins University Comprehensive Transplant Center, Baltimore, Maryland §University of Pennsylvania Comprehensive Transplant Center, Philadelphia, Pennsylvania.
Sally Gustafson
Shikha Mehta
Rhiannon D Reed
Brittany Shelton
Paul A MacLennan
Christine Durand
Jon Snyder
Nicholas Salkowski
Allan Massie
Deirdre Sawinski
Dorry L Segev

Funding

Patient Oriented Research in Kidney Disease and Transplant SurgeryK24DK101828 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SEGEV, DORRY L. · 2014 to 2018
$922k
Long-term outcomes among living kidney donors with isolated medical abnormalitiesK23DK103918 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LOCKE, JAYME ELIZABETH · 2015 to 2019
$899k
Optimal Antiretroviral Therapy During Bone Marrow Transplant in HIV-1 InfectionK23CA177321 · NCI · JOHNS HOPKINS UNIVERSITY · PI DURAND, CHRISTINE MARIE · 2014 to 2018
$808k
NCI NIH HHS K23 CA177321NIDDK NIH HHS K23 DK103918NIDDK NIH HHS K24 DK101828
6 · The paper itself

Abstract

objectiveTo determine the survival benefit of kidney transplantation in human immunodeficiency virus (HIV)-infected patients with end-stage renal disease (ESRD). SUMMARY BACKGROUND DATA: Although kidney transplantation (KT) has emerged as a viable option for select HIV-infected patients, concerns have been raised that risks of KT in HIV-infected patients are higher than those in their HIV-negative counterparts. Despite these increased risks, KT may provide survival benefit for the HIV-infected patient with ESRD, yet this important clinical question remains unanswered.

methodsData from the Scientific Registry of Transplant Recipients were linked to IMS pharmacy fills (January 1, 2001 to October 1, 2012) to identify and study 1431 HIV-infected KT candidates from the first point of active status on the waiting list. Time-dependent Cox regression was used to establish a counterfactual framework for estimating survival benefit of KT.

resultsAdjusted relative risk (aRR) of mortality at 5 years was 79% lower after KT compared with dialysis (aRR 0.21; 95% CI 0.10-0.42; P <0.001), and statistically significant survival benefit was achieved by 194 days of KT. Among patients coinfected with hepatitis C, aRR of mortality at 5 years was 91% lower after KT compared with dialysis (aRR 0.09; 95% CI 0.02-0.46; P < 0.004); however, statistically significant survival benefit was not achieved until 392 days after KT.

conclusionsEvidence suggests that for HIV-infected ESRD patients, KT is associated with a significant survival benefit compared with remaining on dialysis.

Indexed as

RegistriesTissue DonorsAdolescentAdultAgedCohort StudiesComorbidityFemaleGraft RejectionGraft SurvivalHIV InfectionsHumansKidney Failure, ChronicKidney TransplantationLiving DonorsMale

Identifiers

PMID27768622
PMCPMC5285482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.